Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 573 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Novo Nordisk A/S Clear all
Completed Phase 1 Interventional

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

NCT03015207
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0194-0499, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
22 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 11, 2026, 9:53 AM EDT
Completed No phase listed Observational

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

NCT00124293
View directory record Official record
Conditions
Acquired Bleeding Disorder, Trauma
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 11, 2026, 9:53 AM EDT
Recruiting Phase 2 Interventional

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

NCT07395687
View directory record Official record
Conditions
Overweight, Obesity
Interventions
UBT251, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Cypress, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

NCT01046110
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, sitagliptin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
57
States / cities
Huntsville, Alabama • Concord, California • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 11, 2026, 9:53 AM EDT
Active, not recruiting Phase 3 Interventional

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

NCT04775082
View directory record Official record
Conditions
Obesity
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Tucson, Arizona • Denver, Colorado • Meridian, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

NCT06542874
View directory record Official record
Conditions
Type 2 Diabetes (T2D)
Interventions
NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral, Placebo (NNC0487-0111 oral)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

NCT03707990
View directory record Official record
Conditions
Obesity and Overweight
Interventions
NNC0165-1875, Placebo (NNC0165-1875), Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 11, 2026, 9:53 AM EDT
Terminated Phase 2 Interventional

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

NCT01636843
View directory record Official record
Conditions
Inflammation, Rheumatoid Arthritis
Interventions
NNC0109-0012, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
29
States / cities
Huntington Beach, California • La Mesa, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

NCT01885208
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Pell City, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 1 Interventional

A Research Study on Etavopivat in Participants With and Without Liver Disease

NCT06336018
View directory record Official record
Conditions
Liver Diseases
Interventions
Etavopivat
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Orange, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Not applicable Interventional

Impact of an Automated Telephone Intervention on Glycosylated Hemoglobin (HbA1c) in Type 2 Diabetes

NCT00700908
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
automated telephone intervention vs. usual care
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 11, 2026, 9:53 AM EDT
Completed No phase listed Observational

GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus

NCT01950637
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
No treatment given, survey
Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 4 Interventional Results available

Liraglutide Hospital Discharge Trial

NCT01919489
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide + OADs, Glargine + OADs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Miami, Florida • Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT04971785
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA, PTM CILO/FIR
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

IDegLira HIGH Trial

NCT03737240
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
IDegLira, Insulin Degludec (U-100), Insulin Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 11, 2026, 9:53 AM EDT
Completed No phase listed Observational

Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE)

NCT03430154
View directory record Official record
Conditions
Haemophilia A, Haemophilia B, Obesity
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Timeline
2017 – 2018
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 2 Interventional

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

NCT05725902
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 11, 2026, 9:53 AM EDT
Not yet recruiting Phase 2 Interventional

Semaglutide for Low Back Pain

NCT07731256
View directory record Official record
Conditions
Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
Interventions
Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes

NCT01999322
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

NCT01541215
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 17 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

NCT03811535
View directory record Official record
Conditions
Growth Hormone Deficiency in Children
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 11 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery

NCT00914589
View directory record Official record
Conditions
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions
catridecacog, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Atlanta, Georgia • Durham, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 11, 2026, 9:53 AM EDT
Completed No phase listed Observational

Weight Loss in Adults Using Semaglutide (Real-world Study)

NCT07627074
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
237,211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 11, 2026, 9:53 AM EDT
Completed Phase 1 Interventional

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

NCT01511185
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 11, 2026, 9:53 AM EDT